BRAIN expands its IP Portfolio with bioactive Compound MMPI
BRAIN AG has announced the expansion of its IP portfolio to include the MMPI (matrix metalloproteinase inhibitor) peptide. Now owned by BRAIN, the recombinant human bioactive molecule will be manufactured by BRAIN as a proprietary bioactive compound going forward and exclusively used in cosmetics products made by its own group of affiliated companies.
Following the acquisition of the Ludwigstadt-based cosmetics manufacturer, LA Schmitt, and the strategic partnership with MONTEIL Cosmetics International GmbH, announced in early 2012, this expansion of BRAIN’s IP portfolio now is proof of the company’s consistent pursuance of its goal to broaden the value chain in the cosmetics market. Against this backdrop, bioactive compounds for high-tech products will remain a focus for BRAIN in future, as well.
MMPI – a natural bioactive substance to combat skin aging
One common cosmetic problem is the so-called “photoaging” of the skin, which is caused by repeated sun exposure and results in the appearance of wrinkles even at low amounts of UV radiation. At the molecular level, the wrinkles are caused by an increased reduction of skin collagen. This, in turn, is mainly caused by the MMP-1 (matrix metalloproteinase 1) enzyme, which is released in the skin by sunlight and then proceeds to break down the skin’s collagen.
Scientific studies have shown that inhibition of the MMP-1 enzyme reduced the accelerated collagen breakdown in the skin. This is exactly where BRAIN’s MMPI compound comes in. Cosmetic products such as, e.g., sunscreens or day creams containing MMPI as an anti-aging mode of action are already exclusively and successfully sold by the BRAIN group of affiliated companies.
Other news from the department business & finance
